This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutTALZENNA MoATalzenna MoAgBRCA testingIdentifying patientsGuidelinesStudy designStudy designBaseline characteristicsEfficacy & SafetyTALZENNA efficacyPrimary endpoint & subgroup analysisSecondary endpoints: ORRSecondary endpoint: OSExploratory endpoints: DoR & TTRTALZENNA safetySafety and tolerabillityAdverse eventsPatient-reported outcomes with TALZENNAPatient-reported outcomesGHS/QoLBreast symptomsDosingDosingDose recommendation and special populationsDose modifications/managementPatient ProfilesPrescribing InformationSupport & ResourcesSupport & ResourcesMaterialsElevatePersonalising Breast Cancer TreatmentUnderstanding and Optimising PARP Inhibitors for mBCPARP Inhibitors in mBC: the role of Real World Evidence
ESMO Guidelines recommend early gBRCA testing and talazoparib among preferred treatment options1According to ESMO Guidelines:Test
  • In the ABC setting, results from germline genetic testing have therapeutic implications and should be performed as early as possible
  • Appropriate counseling should be provided to patients and their families
Talazoparib is "associated with a PFS benefit, improvement in QoL and a favorable toxicity profile."Treat

Talazoparib is a preferred treatment option for patients with triple-negative ABC and a gBRCA mutation

Talazoparib is a recommended treatment option for patients with ER-positive ABC and a gBRCA mutation

The optimal sequence between a PARPi and ET with or without a CDK4/6 inhibitor is unknown. Given the OS benefit seen with CDK4/6 inhibitors, the panel recommends their use before a PARPi

ESMO Magnitude of Clinical Benefit Score: 4Category I/A: Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity. Strong evidence for efficacy with a substantial clinical benefit, strongly recommended. 

Category I/B: Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity. Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended.
ABC=advanced breast cancer; BRCA=breast cancer susceptibility gene; CDK4/6=cyclin-dependent kinase 4/6; ER=estrogen receptor; ESMO=European Society for Medical Oncology; ET=endocrine therapy; gBRCA=germline breast cancer susceptibility gene; HER2-=human epidermal growth factor receptor 2 negative; mBC=metastatic breast cancer; OS=overall survival; PARP=poly (ADP-ribose) polymerase; PARPi=poly (ADP-ribose) polymerase inhibitor; PFS=progression-free survival; QoL=quality of life. Explore more EMBRACA study design
References:Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649.  TALZENNA® Summary of Product Characteristics. 

Legal Category: S1A 
Further information is available upon request

PP-TAL-IRL-0106 May 2024
gBRCA testing Significantly longer PFS 

Superior to chemotherapy in delaying disease progression4 

 See the data  Mechanism of action

Targeted treatment leads to cancer cell death via PARP inhibition and trapping4

 Explore more
TALZENNA Summary of Product Characteristics Product CharacteristicsLoading

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0832. October 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0832. October 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0832. October 2024